Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Elsterwerda – page 64

1 019 clinical trials in Elsterwerda, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Elsterwerda at a glance
1 019
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 019 trials in Elsterwerda

Open in trial search

Study Comparing Sotorasib and Panitumumab with Other Drug Combinations for Patients with Metastatic Colorectal Cancer and KRAS p.G12C Mutation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Panitumumab
  • Sponsor:Amgen Inc.

Adenocarcinoma gastric+1

Not recruiting

Study Comparing Ramucirumab with Irinotecan, Leucovorin, and 5-FU or Paclitaxel for Patients with Advanced Stomach or Gastroesophageal Cancer After Previous Chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Plasma cell myeloma

Not recruiting

Comparison of intravenous versus subcutaneous isatuximab with lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma patients eligible for transplant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Rectal cancer

Not recruiting

Study Comparing FOLFOX Before Surgery to Risk-Adapted Chemotherapy After Surgery for Patients with Locally Advanced Rectal Cancer and Low Risk of Local Failure

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Heidelberg University

Study of Venetoclax and Blinatumomab for Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Blinatumomab
  • Sponsor:Goethe University Frankfurt

Study on De-escalated Induction Therapy with Methotrexate, Cytarabine, Thiotepa, and Rituximab for Newly Diagnosed Primary CNS Lymphoma Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Busulfan
  • Sponsor:Klinikum Der Landeshauptstadt Stuttgart gKAöR

Follicular lymphoma

Not recruiting

Study on Mosunetuzumab and Lenalidomide for Patients with Follicular Lymphoma After Previous Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Fallopian tube cancer+3

Not recruiting

Study on Mirvetuximab Soravtansine and Carboplatin for Patients with Recurrent Ovarian Cancer Eligible for Platinum-Based Chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AGO Research GmbH

Colitis ulcerative

Not recruiting

Study on the Effects of Fecal Microbiome and Fecal Microbiome Filtrate Capsules for Patients with Active Ulcerative Colitis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Metronidazole
  • Sponsor:Friedrich-Schiller-Universitaet Jena

Fallopian tube cancer+2

Not recruiting

Study on Niraparib and Dostarlimab for Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Not Suitable for Platinum Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Cholangiocarcinoma+1

Not recruiting

Study on Gemcitabine and Cisplatin for Patients After Surgery for Bile Duct or Gallbladder Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:University Medical Center Hamburg-Eppendorf

Cold urticaria

Not recruiting

Study on the Effectiveness and Safety of Barzolvolimab for Patients with Chronic Inducible Urticaria

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab
  • Sponsor:Celldex Therapeutics Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Elsterwerda

What the registry says about research in the country

01 Metabolic Health Research

Clinical investigations focusing on weight management and Type 2 Diabetes treatments, evaluating innovative therapies for improved metabolic outcomes.

  • Weight reduction therapies
  • Diabetes management
  • Cardiovascular risk reduction

Studies combining lifestyle modifications with novel therapeutic approaches for comprehensive metabolic health improvement.

02 Cardiovascular Disease Studies

Research targeting atherosclerotic cardiovascular disease and innovative treatments for various forms of heart failure.

  • Atherosclerosis treatment
  • Heart failure management
  • Cardiac function improvement

Comprehensive evaluation of new therapeutic agents for both preserved and reduced ejection fraction heart failure.

03 Circulatory System Disorders

Advanced clinical research examining treatments for resistant hypertension and atrial fibrillation, focusing on innovative therapeutic approaches.

  • Blood pressure management
  • Stroke prevention
  • Cardiac rhythm disorders

Evaluating next-generation medications for better control of complex cardiovascular conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.